Cargando…

MyoRing Implantation with and without Corneal Collagen Crosslinking for the Management of Keratoconus

PURPOSE: To evaluate the safety and efficacy of femtosecond laser-assisted MyoRing implantation with concurrent corneal collagen crosslinking (CXL) compared to MyoRing alone for the treatment of progressive keratoconus. METHODS: A total of 60 patients were enrolled in this randomized controlled tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadpour, Mehrdad, Masoumi, Ahmad, Dehghan, Mahmoud, Hashemian, Mohammad Nasser, Karami, Shahab Addin, Mahmoudi, Alireza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PUBLISHED BY KNOWLEDGE E 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591835/
https://www.ncbi.nlm.nih.gov/pubmed/33133439
http://dx.doi.org/10.18502/jovr.v15i4.7790
_version_ 1783601068491407360
author Mohammadpour, Mehrdad
Masoumi, Ahmad
Dehghan, Mahmoud
Hashemian, Mohammad Nasser
Karami, Shahab Addin
Mahmoudi, Alireza
author_facet Mohammadpour, Mehrdad
Masoumi, Ahmad
Dehghan, Mahmoud
Hashemian, Mohammad Nasser
Karami, Shahab Addin
Mahmoudi, Alireza
author_sort Mohammadpour, Mehrdad
collection PubMed
description PURPOSE: To evaluate the safety and efficacy of femtosecond laser-assisted MyoRing implantation with concurrent corneal collagen crosslinking (CXL) compared to MyoRing alone for the treatment of progressive keratoconus. METHODS: A total of 60 patients were enrolled in this randomized controlled trial. The patients were randomly allocated into two groups. In the first group, MyoRing was implanted, while in the second, it was inserted in the corneal stroma using the same technique, along with simultaneous CXL. Visual, refractive, topographic, and abberometric outcomes were measured preoperatively and at every postoperative visit. RESULTS: Data of 47 patients were available at the end of the study; 28 in the MyoRing group and 19 in the MyoRing + CXL group. The mean uncorrected distance visual acuity (UDVA) improved from 0.79 [Formula: see text] 0.39 logMAR to 0.52 [Formula: see text] 0.31 logMAR (P [Formula: see text] 0.05) in the MyoRing + CXL group and from 0.65 [Formula: see text] 0.38 logMAR to 0.62 [Formula: see text] 0.23 logMAR (P = 0.70) in the MyoRing group. CDVA changed from 0.33 [Formula: see text] 0.19 logMAR to 0.25 [Formula: see text] 0.16 logMAR (P = 0.10) in the MyoRing + CXL group and 0.32 [Formula: see text] 0.22 logMAR to 0.33 [Formula: see text] 0.17 logMAR (P [Formula: see text] 0.50) in the MyoRing group. The mean keratometry (Km) decreased from 47.5 [Formula: see text] 2.7 D to 43.8 [Formula: see text] 3.2 D (P [Formula: see text] 0.001) in the MyoRing group and 49.3 [Formula: see text] 3.4 D to 45.1 [Formula: see text] 3.0 D (P [Formula: see text] 0.001) in the MyoRing + CXL group. Besides, horizontal coma was significantly lower in the MyoRing + CXL group (P = 0.022). CONCLUSION: MyoRing insertion combined with CXL is a safe and effective method for the treatment of keratoconus. The visual and topographic outcomes were comparable to that for MyoRing insertion after 10 months; however, horizontal coma was significantly lower in the MyoRing + CXL group.
format Online
Article
Text
id pubmed-7591835
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher PUBLISHED BY KNOWLEDGE E
record_format MEDLINE/PubMed
spelling pubmed-75918352020-10-30 MyoRing Implantation with and without Corneal Collagen Crosslinking for the Management of Keratoconus Mohammadpour, Mehrdad Masoumi, Ahmad Dehghan, Mahmoud Hashemian, Mohammad Nasser Karami, Shahab Addin Mahmoudi, Alireza J Ophthalmic Vis Res Original Article PURPOSE: To evaluate the safety and efficacy of femtosecond laser-assisted MyoRing implantation with concurrent corneal collagen crosslinking (CXL) compared to MyoRing alone for the treatment of progressive keratoconus. METHODS: A total of 60 patients were enrolled in this randomized controlled trial. The patients were randomly allocated into two groups. In the first group, MyoRing was implanted, while in the second, it was inserted in the corneal stroma using the same technique, along with simultaneous CXL. Visual, refractive, topographic, and abberometric outcomes were measured preoperatively and at every postoperative visit. RESULTS: Data of 47 patients were available at the end of the study; 28 in the MyoRing group and 19 in the MyoRing + CXL group. The mean uncorrected distance visual acuity (UDVA) improved from 0.79 [Formula: see text] 0.39 logMAR to 0.52 [Formula: see text] 0.31 logMAR (P [Formula: see text] 0.05) in the MyoRing + CXL group and from 0.65 [Formula: see text] 0.38 logMAR to 0.62 [Formula: see text] 0.23 logMAR (P = 0.70) in the MyoRing group. CDVA changed from 0.33 [Formula: see text] 0.19 logMAR to 0.25 [Formula: see text] 0.16 logMAR (P = 0.10) in the MyoRing + CXL group and 0.32 [Formula: see text] 0.22 logMAR to 0.33 [Formula: see text] 0.17 logMAR (P [Formula: see text] 0.50) in the MyoRing group. The mean keratometry (Km) decreased from 47.5 [Formula: see text] 2.7 D to 43.8 [Formula: see text] 3.2 D (P [Formula: see text] 0.001) in the MyoRing group and 49.3 [Formula: see text] 3.4 D to 45.1 [Formula: see text] 3.0 D (P [Formula: see text] 0.001) in the MyoRing + CXL group. Besides, horizontal coma was significantly lower in the MyoRing + CXL group (P = 0.022). CONCLUSION: MyoRing insertion combined with CXL is a safe and effective method for the treatment of keratoconus. The visual and topographic outcomes were comparable to that for MyoRing insertion after 10 months; however, horizontal coma was significantly lower in the MyoRing + CXL group. PUBLISHED BY KNOWLEDGE E 2020-10-25 /pmc/articles/PMC7591835/ /pubmed/33133439 http://dx.doi.org/10.18502/jovr.v15i4.7790 Text en Copyright © 2020 Mohammadpour et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Original Article
Mohammadpour, Mehrdad
Masoumi, Ahmad
Dehghan, Mahmoud
Hashemian, Mohammad Nasser
Karami, Shahab Addin
Mahmoudi, Alireza
MyoRing Implantation with and without Corneal Collagen Crosslinking for the Management of Keratoconus
title MyoRing Implantation with and without Corneal Collagen Crosslinking for the Management of Keratoconus
title_full MyoRing Implantation with and without Corneal Collagen Crosslinking for the Management of Keratoconus
title_fullStr MyoRing Implantation with and without Corneal Collagen Crosslinking for the Management of Keratoconus
title_full_unstemmed MyoRing Implantation with and without Corneal Collagen Crosslinking for the Management of Keratoconus
title_short MyoRing Implantation with and without Corneal Collagen Crosslinking for the Management of Keratoconus
title_sort myoring implantation with and without corneal collagen crosslinking for the management of keratoconus
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591835/
https://www.ncbi.nlm.nih.gov/pubmed/33133439
http://dx.doi.org/10.18502/jovr.v15i4.7790
work_keys_str_mv AT mohammadpourmehrdad myoringimplantationwithandwithoutcornealcollagencrosslinkingforthemanagementofkeratoconus
AT masoumiahmad myoringimplantationwithandwithoutcornealcollagencrosslinkingforthemanagementofkeratoconus
AT dehghanmahmoud myoringimplantationwithandwithoutcornealcollagencrosslinkingforthemanagementofkeratoconus
AT hashemianmohammadnasser myoringimplantationwithandwithoutcornealcollagencrosslinkingforthemanagementofkeratoconus
AT karamishahabaddin myoringimplantationwithandwithoutcornealcollagencrosslinkingforthemanagementofkeratoconus
AT mahmoudialireza myoringimplantationwithandwithoutcornealcollagencrosslinkingforthemanagementofkeratoconus